Asceniv is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How do you pay?

How to pay the least

Given by your care team

Billed by the clinic

Asceniv is given by a doctor or nurse, not picked up at a pharmacy.

  1. Ask your care team or your plan what you’d pay before your visit.

Compare every option

Question
Brand nameAsceniv
Authorized generichuman immunoglobulin G
Regular generichuman immunoglobulin G
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Asceniv?
The original
–
–

Brand nameThe maker’s card

ADMA ADvantage Ig Patient Support Program

Savings card from ADMA Biologics

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $75 a year

Sign up on asceniv.com 

In the maker’s words

“The program covers up to a fixed amount of out-of-pocket costs per calendar year for eligible patients, after the patient has paid the first $75 of their required deductible, copay or coinsurance, and administration amount.”

From the maker’s offer on asceniv.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Asceniv itself, from the same company, sold without the brand name, and usually for less. For now Asceniv is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Asceniv is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

ASCENIV (immune globulin intravenous, human – slra) is a 10% immune globulin liquid for intravenous injection, indicated for the treatment of primary humoral immunodeficiency (PI) in adults and pediatric patients 2 years of age and older.

Source: the FDA label for Asceniv (ADMA Biologics, Inc.), September 29, 2026. Full label on DailyMed 

Good to know